期刊
ATHEROSCLEROSIS
卷 220, 期 1, 页码 3-10出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2011.06.041
关键词
Tanshinone IIA; Atherosclerosis; Anti-oxidant; Oxidized LDL; Myocardial infarction; Cardiac hypertrophy
资金
- National Natural Science Foundation of China [30472022]
- National Major Project Key New Drug Creation and Manufacturing Program [2011ZX09401-307, 2009ZX09102-152, 2009ZX09303-007]
- People's Government of Guangdong Province [2003A30904]
- Ministry of Education [104146]
- Key Projects in Modernization of Traditional Chinese Medicine in Guangdong Province [2003B31713]
- Guangzhou City Scientific Bureau [2003Z1-E5011]
- National Health & Medical Research Council of Australia
- National Heart Foundation of Australia
- Diabetes Australia Research Trust
- Ministry of Education of the People's Republic of China
Tanshinone IIA (TS), a pharmacologically active component isolated from the rhizome of the Chinese herb Salvia miltiorrhiza Bunge (Danshen), has been clinically used in Asian countries for the prevention and treatment of coronary heart disease. Recently, the pharmacological properties of TS in the cardiovascular system have attracted great interest. Emerging experimental studies and clinical trials have demonstrated that TS prevents atherogenesis as well as cardiac injury and hypertrophy. In atherosclerosis, TS acts by inhibiting LDL oxidation, monocyte adhesion to endothelium, smooth muscle cell migration and proliferation, macrophage cholesterol accumulation, proinflammatory cytokine expression and platelet aggregation. TS has some activity and potential to stabilize atherosclerotic plaques. The cardioprotective effects of TS are mainly related to its anti-oxidant and anti-inflammatory actions. In this review, we focus on the protective effects and the mechanism of action of TS in the cardiovascular system, and provide a novel perspective on clinical use of TS. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据